Tags

Type your tag names separated by a space and hit enter

Comparison of meloxicam and a glucosamine-chondroitin supplement in management of feline osteoarthritis. A double-blind randomised, placebo-controlled, prospective trial.
Vet Comp Orthop Traumatol 2014; 27(1):20-6VC

Abstract

OBJECTIVE

To compare the efficacy of meloxicam and a glucosamine-chondroitin (Glu-Ch) supplement in the management of feline osteoarthritis (OA).

METHODS

Prospective, blinded, randomized clinical trial. Cats over eight years of age with clinical signs of chronic OA were assigned to one of two groups and Glu-Ch or meloxicam was administered orally for 70 days, followed by a placebo until day 98. Cats were assessed by a veterinarian on five occasions and the owner completed an assessment form at the same time.

RESULTS

Data were collected from thirty cats. Pre-treatment disease scores were significantly higher in the meloxicam group for owner mobility (p=0.01) and veterinary lameness (p=0.02). Owner mobility scores at day 14 (p=0.01) and day 42 (p=0.002) were significantly improved compared to pre-treatment scores for the meloxicam group. When meloxicam and Glu-Ch were discontinued and the placebo commenced, a significant proportion of the meloxicam group showed worsening of all the owner-assessed scores between day 70 and day 98, when compared to the Glu-Ch group (mobility p=0.01; activity p=0.02; temperament p=0.04; lifestyle p=0.01).

CONCLUSIONS

Treatment with meloxicam resulted in a significant improvement in mobility and activity levels of cats with OA until the placebo was introduced. A greater proportion of cats receiving meloxicam medication showed a significant worsening of owner assessment scores once the placed was introduced, when compared to the Glu-Ch group.

Authors+Show Affiliations

Rui M. Sul, LMV MRCVS, Small Animal Hospital, School of Veterinary Medicine, University of Glasgow, 464 Bearsden Road, Glasgow G61 1QH, United Kingdom, Phone: +44 141 330 5848, Fax: +44 141 330 3663, Email: r.sul.1@research.gla.ac.uk.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

24146058

Citation

Sul, R M., et al. "Comparison of Meloxicam and a Glucosamine-chondroitin Supplement in Management of Feline Osteoarthritis. a Double-blind Randomised, Placebo-controlled, Prospective Trial." Veterinary and Comparative Orthopaedics and Traumatology : V.C.O.T, vol. 27, no. 1, 2014, pp. 20-6.
Sul RM, Chase D, Parkin T, et al. Comparison of meloxicam and a glucosamine-chondroitin supplement in management of feline osteoarthritis. A double-blind randomised, placebo-controlled, prospective trial. Vet Comp Orthop Traumatol. 2014;27(1):20-6.
Sul, R. M., Chase, D., Parkin, T., & Bennett, D. (2014). Comparison of meloxicam and a glucosamine-chondroitin supplement in management of feline osteoarthritis. A double-blind randomised, placebo-controlled, prospective trial. Veterinary and Comparative Orthopaedics and Traumatology : V.C.O.T, 27(1), pp. 20-6. doi:10.3415/VCOT-12-11-0139.
Sul RM, et al. Comparison of Meloxicam and a Glucosamine-chondroitin Supplement in Management of Feline Osteoarthritis. a Double-blind Randomised, Placebo-controlled, Prospective Trial. Vet Comp Orthop Traumatol. 2014;27(1):20-6. PubMed PMID: 24146058.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of meloxicam and a glucosamine-chondroitin supplement in management of feline osteoarthritis. A double-blind randomised, placebo-controlled, prospective trial. AU - Sul,R M, AU - Chase,D, AU - Parkin,T, AU - Bennett,D, Y1 - 2013/10/22/ PY - 2012/11/14/received PY - 2013/08/19/accepted PY - 2013/10/23/entrez PY - 2013/10/23/pubmed PY - 2014/9/16/medline KW - Feline KW - chondroitin KW - glucosamine KW - meloxicam KW - osteoarthritis SP - 20 EP - 6 JF - Veterinary and comparative orthopaedics and traumatology : V.C.O.T JO - Vet Comp Orthop Traumatol VL - 27 IS - 1 N2 - OBJECTIVE: To compare the efficacy of meloxicam and a glucosamine-chondroitin (Glu-Ch) supplement in the management of feline osteoarthritis (OA). METHODS: Prospective, blinded, randomized clinical trial. Cats over eight years of age with clinical signs of chronic OA were assigned to one of two groups and Glu-Ch or meloxicam was administered orally for 70 days, followed by a placebo until day 98. Cats were assessed by a veterinarian on five occasions and the owner completed an assessment form at the same time. RESULTS: Data were collected from thirty cats. Pre-treatment disease scores were significantly higher in the meloxicam group for owner mobility (p=0.01) and veterinary lameness (p=0.02). Owner mobility scores at day 14 (p=0.01) and day 42 (p=0.002) were significantly improved compared to pre-treatment scores for the meloxicam group. When meloxicam and Glu-Ch were discontinued and the placebo commenced, a significant proportion of the meloxicam group showed worsening of all the owner-assessed scores between day 70 and day 98, when compared to the Glu-Ch group (mobility p=0.01; activity p=0.02; temperament p=0.04; lifestyle p=0.01). CONCLUSIONS: Treatment with meloxicam resulted in a significant improvement in mobility and activity levels of cats with OA until the placebo was introduced. A greater proportion of cats receiving meloxicam medication showed a significant worsening of owner assessment scores once the placed was introduced, when compared to the Glu-Ch group. SN - 2567-6911 UR - https://www.unboundmedicine.com/medline/citation/24146058/Comparison_of_meloxicam_and_a_glucosamine_chondroitin_supplement_in_management_of_feline_osteoarthritis__A_double_blind_randomised_placebo_controlled_prospective_trial_ L2 - http://www.thieme-connect.com/DOI/DOI?10.3415/VCOT-12-11-0139 DB - PRIME DP - Unbound Medicine ER -